Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World
16 März 2020 - 9:09PM
Biogen Foundation Commits $10 Million to Support COVID-19 Relief
Efforts in the U.S. and Around the World
Biogen Inc
. (Nasdaq: BIIB) today announced that
the Biogen Foundation has committed $10 million to support global
response efforts and communities around the world impacted by the
COVID-19 pandemic. The funds will be used to address immediate
critical needs, with the majority of donations going to support
non-profit organizations in the U.S., including Massachusetts and
North Carolina, in Italy and in other impacted countries worldwide.
This donation will be used to help expand testing options, ease the
strain on medical systems, provide training for front line health
workers and support access to necessities like food. This adds to
the donation made by Biogen China to the Red Cross Society of
China.
The company has also provided medical equipment and supplies to
Partners HealthCare in Massachusetts, to help diagnose COVID-19 in
a greater number of people. Partners HealthCare is one of the
largest providers of healthcare services in the Boston area. Biogen
will also be supporting Massachusetts General Hospital and Brigham
and Women’s Hospital directly as they work on the front line to
treat and contain the virus.
“We are deeply affected by the impact of COVID-19 globally and
we understand the critical importance of access to testing and
other materials to support healthcare providers,” said Michel
Vounatsos, CEO at Biogen. “It is vital that we act immediately to
support those who are on the front lines caring for the health and
well-being in all communities affected around the world. Our hope
is that this commitment will support these courageous
organizations, and the vulnerable, during this unprecedented
time.”
“This pandemic is precipitating a series of unprecedented
challenges and it is having a critical impact in our community and
on people around the world,” said Anne Klibanski, M.D., President
and CEO of Partners HealthCare. “I believe it is how we rise to
meet these challenges that defines us.”
About the Biogen Foundation The Biogen
Foundation supports access to science education and to essential
human services for children and their families in the communities
in which Biogen facilities are located. The Biogen Foundation is
committed to sparking a passion for science and discovery,
supporting effective science education initiatives and
strengthening efforts to make science education and science careers
accessible to diverse populations.
About BiogenAt Biogen, our mission is clear: we
are pioneers in neuroscience. Biogen discovers, develops and
delivers worldwide innovative therapies for people living with
serious neurological and neurodegenerative diseases as well as
related therapeutic adjacencies. One of the world’s first global
biotechnology companies, Biogen was founded in 1978 by Charles
Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners
Walter Gilbert and Phillip Sharp. Today Biogen has the leading
portfolio of medicines to treat multiple sclerosis, has introduced
the first approved treatment for spinal muscular atrophy,
commercializes biosimilars of advanced biologics and is focused on
advancing research programs in multiple sclerosis and
neuroimmunology, Alzheimer’s disease and dementia, neuromuscular
disorders, movement disorders, ophthalmology, immunology,
neurocognitive disorders, acute neurology and pain.
We routinely post information that may be important to investors
on our website at www.biogen.com. Follow us on social media
– Twitter, LinkedIn, Facebook, YouTube.
MEDIA CONTACT:David Caouette+ 1 617 679
4945public.affairs@biogen.com |
INVESTOR CONTACT:Joe Mara+1 781 464 2442IR@biogen.com |
|
|
Biogen (TG:IDP)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Biogen (TG:IDP)
Historical Stock Chart
Von Apr 2023 bis Apr 2024